[12] Patent
[11] Patent No.:GC0007601  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  		 Number of the Decision to Grant the Patent:2018/126086
Date of the Decision to Grant the Patent:16/Apr/2018

[21] Application No.:GC 2013-25823

[22] Filing Date:17/11/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
19/11/2012
18/7/2013
 61/728,018
61/847,860

[72] Inventors:1- Arnab Chatterjee،2- Advait Nagle،3- Prasuna Paraselli،4- Ravinder Reddy Kondreddi،5- Seh Yong Leong،6- Pranab Mishra،7- Robert Moreau،8- Jason Thomas Roland،9- Wei Lin Sandra Sim،10- Simon Oliver،11- Liying Jocelyn Tan،12- Bryan KS Yeung،13- Bin Zou،14- Venkatataiah Bollu

[73] Owner: Novartis International Pharmaceutical, 131 Front Street, P.O. Box HM 2899, Hamilton, Bermuda

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

   

[51]IPC:
Int. Cl.: [C07D487/04, C07D487/14, C07D519/00, A61K31/4985, A61P33/06, A61P33/02] (2006.01)

[56] Cited Documents:

-WO 2011006143 A2 (IRM LLC; CHATTERJEEARNAB K [US]; NAGLE ADVAIT [US]; WU TAO[US]; TULL) 13 January 2011
-US 2007219218 A1 (YU WENSHENG [US] ET AL) 20 September 2007  
Examiner: PH. Mohammad S. AlMousa

[54] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
[57] Abstract: The present invention provides compounds of formula I: ,or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.
No. of claims: 14


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.